COLL — COLLEGIUM PHARMACEUTICAL INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About COLLEGIUM PHARMACEUTICAL INC (COLL)
COLLEGIUM PHARMACEUTICAL INC (COLL) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $12M. Across recent filings, tracked investors recorded 3 new positions, 0 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in COLL
How many top investors track COLL
A small number of top investors own this.
COLL Ownership Composition
How COLLEGIUM PHARMACEUTICAL INC is held across tracked investor types, based on reported 13F positions.
- Other100.0%
Tracked investors reporting COLL
- Izzy EnglanderMar 31, 2026Millennium ManagementShares360.8KValue$11.9M% Portfolio0.00%
- Ken GriffinMar 31, 2026Citadel AdvisorsShares121.4KValue$4M% Portfolio0.00%
- Paul Tudor JonesMar 31, 2026Tudor Investment CorpShares14KValue$461.5K% Portfolio0.00%
Recent activity
- $795.2KFeb 17, 2026
- $461.5KMay 15, 2026
- $3.3MFeb 17, 2026
Frequently asked questions
- How many institutional investors hold COLL?
- 3 tracked institutional investors disclosed a position in COLL (COLLEGIUM PHARMACEUTICAL INC) in their most recent 13F filing.
- Who is the largest institutional holder of COLL?
- Izzy Englander, Millennium Management, holds the largest disclosed position in COLL, valued at $12M.
- Did institutional ownership of COLL increase or decrease?
- Across recent 13F filings, tracked investors recorded 3 new positions, 0 increased, 0 reduced, and 0 fully exited COLL.
- Where does this COLL ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.